Wockhardt will be in focus after the US FDA approved ZAYNICH, a novel intravenous antibiotic combining cefepime and zidebactam for complicated urinary tract infections. The drug targets multidrug-resistant Gram-negative pathogens and showed strong efficacy in Phase 3 trials. The approval highlights growing urgency around antimicrobial resistance and limited treatment options.
Market Samachar is a news aggregator. This article was originally published by Stocks-Markets-Economic Times. Tap the button above to read the full story on their site.